Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 in COPD
NCT07828353Phase 3Not yet recruiting
- Sponsor
- Regend Therapeutics
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of autologous bronchial basal cells in chronic obstructive pulmonary disease (COPD), sponsored by Regend Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
autologous bronchial basal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07828353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828353.